The Economist Intelligence Unit research
identifies significant gaps between recommended guidelines and
clinical practice for stroke prevention across 20 countries
New research released today by The Economist Intelligence Unit
(EIU), a division of The Economist and a leader in global business
intelligence, revealed that on average, more than 75 percent of
people aged 65 and older worldwide are not being screened for
atrial fibrillation (AF) and other common stroke risk factors
during routine primary care examinations, even though this
population is at high risk for stroke. The EIU “Preventing Stroke:
Uneven Progress” report, sponsored by The Bristol-Myers
Squibb-Pfizer Alliance, conducted an analysis of 20 countries and
found that efforts to screen people for stroke risk factors
including AF and hypertension varied widely, even in countries with
established health care and developed economies.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170921005344/en/
“Stroke is the second leading cause of death globally,
accounting for 6.2 million deaths,1 but is nearly 80 percent
preventable,”2 said Becca Lipman, editor of the EIU’s thought
leadership division and of this report. “Our hope is that this
research will elevate the awareness and urgency surrounding
screening for stroke risk factors including AF and hypertension and
offer suggestions on what can be done on a country-by-country level
to further improve prevention. There are critical and urgent
opportunities to improve screening, so that fewer people suffer the
devastating consequences of stroke.”
The “Preventing Stroke: Uneven Progress” report considered
policy efforts to assess and reduce risks of stroke across
different aspects including awareness, screening practices and
policies. Key findings include:
- There is a disconnect between
established best practices and everyday clinical practice. For
example, there are gaps in the training of health care
professionals to properly identify and treat stroke risks.
- Screening for AF and hypertension
remains low and is not regularly performed in clinical
practice.
- Future policies should focus on
strategies to improve awareness of stroke risk factors, implement
systematic and/or opportunistic screenings, and include both
individual and population-based health-intervention
approaches.
“People with AF are at least three times more likely to have a
stroke than those without this condition,”3,4,5 said Rory O’Connor,
MD, Chief Medical Officer, Pfizer Internal Medicine. “Even modest
improvements in diagnosis and treatment of stroke risk factors
including AF – supported by collaborations across healthcare
providers, advocates, policymakers and the private sector – could
potentially prevent many strokes and related deaths.”6
“We are committed to supporting increased early detection and
diagnosis with the goal of ultimately reducing the prevalence of
AF-related strokes globally,” said Christoph Koenen, MD, MBA, VP,
Development Lead, Cardiovascular Medicine, Bristol-Myers
Squibb. “By working to implement research-driven approaches, The
Bristol-Myers Squibb and Pfizer Alliance is aiming to close gaps
that are currently leaving undiagnosed and under-treated AF
patients at unnecessary risk for stroke.”
About The Economist Research Initiative
Bristol-Myers Squibb and Pfizer sponsored the Preventing Stroke:
Uneven Progress initiative conducted by The Economist Intelligence
Unit (EIU), a world leader in global business intelligence and the
business-to-business arm of The Economist Group, which publishes
The Economist newspaper. The EIU researched the progress in stroke
prevention and policies made by 20 different countries – Australia,
Belgium, Brazil, Canada, China, France, Germany, Italy, Japan,
Mexico, the Netherlands, Norway, Russia, Saudi Arabia, South
Africa, Spain, Sweden, Turkey, the UK and the United States. The
EIU developed a scorecard to assess each country’s performance
across four different categories and conducted in-depth interviews
with experts on cardiovascular health and stroke, which were
included in the final report. For more information and/or to access
the research, please visit
www.eiuperspectives.economist.com/healthcare/policy-approaches-stroke-prevention.
About the Bristol-Myers Squibb and Pfizer Alliance
The Bristol-Myers Squibb and Pfizer Alliance is committed to
driving education and awareness about atrial fibrillation and
venous thromboembolism. With long-standing cardiovascular
leadership, global scale and expertise in this field, the Alliance
strives to implement global, research-driven approaches to
illuminate and address the unmet needs around strokes related to
non-valvular atrial fibrillation, which are often fatal or
debilitating.7 Through collaborations with non-profit
organizations, the Alliance aims to provide patients, physicians,
and decision makers with the information they need to understand
and take appropriate action on risk factors associated with stroke
and other cardiovascular conditions.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
About Pfizer Inc.: Working together for a healthier
world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.pfizer.com. In
addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.
1 Top 10 Causes of Death. (webpage) World Health Organization.
Accessed on August 10, 2017.
http://www.who.int/mediacentre/factsheets/fs310/en/.2 Myth vs.
Fact: Stroke Facts (webpage). National Stroke Association. Accessed
on August 10, 2017.
http://www.stroke.org/understand-stroke/what-stroke/stroke-facts3
January, C. T. (2014). ACC/AHA/HRS Guideline for the Management of
Patients with Atrial Fibrillation. Circulation, 130, E212-E212.
doi:10.1161/CIR.0000000000000041/-/DC1.4 Wolf PA, Abbott RD, Kannel
WB. Atrial fibrillation as an independent risk factor for stroke:
the Framingham study. Stroke 1991;22: 983–8.5 Spodato LA, Cipriano
LE, Saposnik G. (2015). Diagnosis of atrial fibrillation after
stroke and transient ischaemic attack: a systematic review and
meta-analysis. Lancet Neurol 2015; 14: 377–87.6 Stroke Facts. The
U.S. Centers for Disease Control and Prevention (CDC). (webpage)
Accessed on August 10, 2017. https://www.cdc.gov/stroke/facts.htm7
Ben Freedman, Tatjana S. Potpara, and Gregory Y H Lip, "Stroke
prevention in atrial fibrillation," The Lancet 388, no. 10046
(2016): , doi:10.1016/s0140-6736(16)31257-0.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921005344/en/
Bristol-Myers SquibbMedia:Rob Perry,
407-492-4616rob.perry@bms.comorInvestors:Timothy Power,
609-252-7509timothy.power@bms.comorPfizer Inc.Media:Steven
Danehy, 212-733-1538steven.danehy@pfizer.comorInvestors:Ryan
Crowe, 212-733-8160ryan.crowe@pfizer.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024